-+ 0.00%
-+ 0.00%
-+ 0.00%

Structure Therapeutics Reports Topline Data From ACCESS Program For Aleniglipron

Benzinga·12/08/2025 13:07:57
Listen to the news

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation 

Placebo-adjusted mean weight loss up to 15.3% (35.5 lbs) observed with 240 mg dose in the exploratory ACCESS II study at 36 weeks

No adverse event-related treatment discontinuations observed when starting at lower 2.5 mg dose in ACCESS Open Label Extension and Body Composition Study

Data comprehensively support and inform advancement to Phase 3 clinical development program in mid-2026

Company to host conference call today at 8:30 a.m. Eastern Time